The Regulatory Affairs Professionals Society (RAPS) is seeking to increase its presence in Europe and expanding its European team.
The Regulatory Affairs Professionals Society (RAPS) is seeking to increase its presence in Europe and expanding its European team.
In the last year, the society’s European membership base has grown by approximately 19% to more than 1,500 people in 29 countries. It now plans to spend more than 2 million euros over the next three years by launching new events and resources to serve the needs of regulatory professionals in the region.
“Europe has a vibrant and progressive healthcare products community and many of our existing regulatory professionals are working here, so increasing our investment in Europe was a natural next step for RAPS,” said RAPS executive director Paul Brooks. “Healthcare is a global business, and with more than 15,000 members in over 80 countries, we are well aware of the challenges regulatory professionals face worldwide. Our own research has shown that in Europe more than 65% of professionals in the healthcare product industries have multi-regional or worldwide responsibilities.”
RAPS plans “a substantial increase” in European staff, plus a series of new events, including a RAPS Roadshow (“Examining the New European Medical Device Regulations”) on May 4 in Munich and a workshop (“EU Regulatory Essentials, Medical Device and In Vitro Diagnostics: Transitioning from Current Directives to New Regulations”) on July 4-5 in Brussels.
Brooks continued: “In highly regulated environments such as the pharmaceutical and medical device sectors, there is a greater need than ever for regulatory professionals to stay up to date on the latest regulatory developments. In particular, changes to medical device regulations in Europe present a huge challenge to manufacturers and should be high on the industry’s agenda as we move towards the 2020 deadline.”
Also, in May RAPS will host a four-part virtual program called “Understanding the New EU Medical Device and IVD Regulations.” It has produced an interactive guide to the new EU Medical Device and IVD Regulations.
Additionally, the society is looking to increase awareness of its Regulatory Affairs Certification (RAC). The RAC is the only professional certification specifically for those in the healthcare product regulatory field, testing knowledge and critical thinking relating to the international practice of regulatory affairs, according to the organization. Four RAC credentials are available, including one focused on European regulations. Currently, more than 4,000 individuals worldwide are RAC-credentialed, it added.
Philip Ward is the European Editor for Applied Clinical Trials
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.